Revolution Medicine has wowed investors and analysts by announcing dazzling data from its Phase III RASolute 302 trial ...

Patients with RAS G12D non-small cell lung cancer remain a population with a significant unmet medical need for targeted therapeutic options,” said Jonathan Riess M.D., medical director of thoracic ...

Early results presented at a cancer research conference showed tumor shrinkage and slowed disease progression in patients who ...

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...

FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...

This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn.Boehringer Ingelheim today announced that The New ...

Chemotherapy has been the standard for previously untreated advanced or metastatic HER2-mutant lung cancer. In this phase I ...

In the ARROW trial, researchers found that different RET fusion partners affected the durability of patients' responses, a finding that could be useful for guiding treatment.

Mr. Kim, 62 years old, a man preparing for retirement, was an office worker diligently attending to his job just a year ago.

An investigational targeted therapy doubled survival compared with standard chemotherapy for pretreated individuals with ...

Detecting whether osteosarcoma, a rare but aggressive bone cancer that most often affects children and adolescents, has ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...